Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07587229 · ClinicalTrials.gov registry record
Alternative Splicing Based Prediction of Chemotherapy Response in Gastric Cancer
A clinical trial, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- 329
- Enrollment target
NCT07587229: Recruiting study, sponsored by City of Hope Medical Center.
NCT07587229 is a clinical trial that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 329 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07587229 is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- 329 participants
- Enrollment target
Study Summary
This study aims to develop a model to predict response to chemotherapy in gastric cancer using RNA splicing information from tumor tissue. By analyzing genetic patterns and applying machine learning, the study seeks to identify patients who are less likely to benefit from treatment, helping guide clinical decision-making.
Primary Outcome
Treatment response was defined based on recurrence-free survival (RFS). Patients who developed recurrence within 3 years after curative surgery were classified as non-responders, whereas those without recurrence were classified as responders.
Interventions
- OTHER Observational study (no intervention)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 329 participants |
| Start Date | 2026-05-01 |
| Est. Completion | 2027-01-01 |
What NCT07587229 shows while recruiting
NCT07587229 is an observational study that tracks outcomes without assigning an intervention. The registered 329 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Observational study (no intervention) is the first listed.
NCT07587229 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07587229 about?
NCT07587229 is a clinical study titled "Alternative Splicing Based Prediction of Chemotherapy Response in Gastric Cancer". This study aims to develop a model to predict response to chemotherapy in gastric cancer using RNA splicing information from tumor tissue. By analyzing genetic patterns and applying machine learning, the study seeks to identify patients who are less likely to benefit from treatment, helping guide c...
What is the current status of trial NCT07587229?
This trial is currently recruiting. The enrollment target is 329 participants. The study started on 2026-05-01. Estimated completion is 2027-01-01.
What interventions are being tested in trial NCT07587229?
The interventions under investigation include: Observational study (no intervention) (OTHER).
Who is sponsoring clinical trial NCT07587229?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06036446 · 329 participants · NA
LATe Cerclage in High-risk Pregnancies (LATCH)
- NCT00359684 · 330 participants
Use of Cysteamine in the Treatment of Cystinosis
- NCT03817502 · 330 participants · Phase 3
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
- NCT03922724 · 330 participants · Phase 2
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI